IKZF2 and myeloid leukemia: IKZF2 (also known as Helios), a zinc-finger transcription factor, is pivotal in regulating immune homeostasis and identified as a potential immunotherapeutic target through structural studies.480,481 Particularly relevant to AML, IKZF2 influences the leukemic stem cells (LSCs) by promoting self-renewal and inhibiting myeloid differentiation.482 The targeted degradation of IKZF2 emerges as a rational therapeutic strategy for myeloid leukemias.